Hyperfine Inc. has announced interim results from the CARE PMR study, which were presented at the 2025 Alzheimer's Association International Conference in Toronto, Canada. The study evaluates the efficacy of Hyperfine's Swoop® AI-Powered Portable MRI System in detecting ARIA-E in patients undergoing amyloid-targeting therapies such as Lecanemab. The Swoop® system demonstrated a 100% sensitivity rate in identifying mild to moderate ARIA-E, offering a promising solution to the logistical and financial challenges associated with conventional MRI systems. Researchers from Washington University School of Medicine in St. Louis reported findings from 31 Alzheimer's patients, who were scanned using the Swoop® system within one week of their clinical high-field MRI scans. While the ultra-low-field MRI shows potential as a triage tool, high-field MRI may still be required for comprehensive evaluations in certain cases.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.